

Daouda Sissoko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6649838/publications.pdf>

Version: 2024-02-01

26
papers

3,006
citations

394390

19
h-index

377849

34
g-index

35
all docs

35
docs citations

35
times ranked

3658
citing authors

#	ARTICLE	IF	CITATIONS
1	Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Réunion. <i>Epidemiology and Infection</i> , 2009, 137, 534-541.	2.1	435
2	A Major Epidemic of Chikungunya Virus Infection on Réunion Island, France, 2005–2006. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 727-731.	1.4	419
3	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	8.4	382
4	Post-Epidemic Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and Associated Factors over a 15-Month Period. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e389.	3.0	294
5	A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 727-31.	1.4	205
6	Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days. <i>Clinical Infectious Diseases</i> , 2016, 63, 1353-1356.	5.8	201
7	Seroprevalence and Risk Factors of Chikungunya Virus Infection in Mayotte, Indian Ocean, 2005-2006: A Population-Based Survey. <i>PLoS ONE</i> , 2008, 3, e3066.	2.5	158
8	Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005389.	3.0	153
9	Rift Valley Fever, Mayotte, 2007–2008. <i>Emerging Infectious Diseases</i> , 2009, 15, 568-570.	4.3	108
10	Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. <i>The Lancet Global Health</i> , 2017, 5, e80-e88.	6.3	100
11	Factors associated with persistence of arthralgia among chikungunya virus-infected travellers: Report of 42 French cases. <i>Journal of Clinical Virology</i> , 2010, 47, 85-88.	3.1	84
12	Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw793.	5.8	70
13	Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. <i>BMJ: British Medical Journal</i> , 2004, 328, 249-0.	2.3	62
14	Outbreak of Chikungunya fever in Mayotte, Comoros archipelago, 2005–2006. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008, 102, 780-786.	1.8	58
15	Field evaluation of clinical features during chikungunya outbreak in Mayotte, 2005-2006. <i>Tropical Medicine and International Health</i> , 2010, 15, 600-7.	2.3	55
16	Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 195-202.	4.0	38
17	Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. <i>HIV Medicine</i> , 2006, 7, 140-145.	2.2	31
18	The Influence of Compositional and Contextual Factors on Non-Receipt of Basic Vaccines among Children of 12-23-Month Old in India: A Multilevel Analysis. <i>PLoS ONE</i> , 2014, 9, e106528.	2.5	24

#	ARTICLE	IF	CITATIONS
19	Prevalence of type 2 diabetes and other cardiovascular risk factors in Mayotte in 2008: The MAYDIA study. <i>Diabetes and Metabolism</i> , 2011, 37, 201-207.	2.9	21
20	Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005545.	3.0	17
21	How to treat Ebola virus infections? A lesson from the field. <i>Current Opinion in Virology</i> , 2017, 24, 9-15.	5.4	15
22	Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1377-1388.	3.0	13
23	Seroepidemiology of Dengue Virus in Mayotte, Indian Ocean, 2006. <i>PLoS ONE</i> , 2010, 5, e14141.	2.5	12
24	Transmission Dynamics and Disease Severity in Children Infected With East Central South African (ECSA) or ECSA-diverged Clades of Chikungunya Virus. <i>Clinical Infectious Diseases</i> , 2019, 68, 171-172.	5.8	5
25	Seroprevalence of Chikungunya Virus after Its Emergence in Brazil. <i>Emerging Infectious Diseases</i> , 2018, 24, 1773-1773.	4.3	4
26	High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea. <i>IDCases</i> , 2022, 27, e01412.	0.9	2